Navigating Prolactinomas in Pregnancy: An Evidence-Based Approach for Optimal Maternal and Fetal Outcomes

Navigating Prolactinomas in Pregnancy: An Evidence-Based Approach for Optimal Maternal and Fetal Outcomes

Prolactinomas, common pituitary adenomas in reproductive-age women, challenge pregnancy management due to risks of tumor growth and hormonal shifts. This article reviews current strategies for diagnosis, treatment, and monitoring before, during, and after pregnancy to ensure safety and fertility restoration.
Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up

Durable Efficacy and Safety of Avutometinib plus Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Insights from a 2-Year ENGOT-OV60/GOG-3052/RAMP 201 Follow-up

A 2-year follow-up of the ENGOT-OV60/GOG-3052/RAMP 201 trial confirms that the combination of avutometinib and defactinib offers sustained benefit and manageable safety in recurrent low-grade serous ovarian cancer, particularly in patients with KRAS mutations.
Medicaid Expansion and Severe Maternal Morbidity: Evaluating the Impact of the Affordable Care Act on Delivery Outcomes

Medicaid Expansion and Severe Maternal Morbidity: Evaluating the Impact of the Affordable Care Act on Delivery Outcomes

This study analyzes the ACA Medicaid expansion's effect on severe maternal morbidity during delivery hospitalizations, finding increased Medicaid coverage but no significant change in severe maternal morbidity rates, underscoring the need for further clinical and policy interventions.
Impact of Third-Trimester Energy Restriction on Postnatal Maternal and Infant Body Composition After Gestational Diabetes: Insights from the DiGest Follow-up Study

Impact of Third-Trimester Energy Restriction on Postnatal Maternal and Infant Body Composition After Gestational Diabetes: Insights from the DiGest Follow-up Study

Third-trimester energy restriction in women with gestational diabetes and elevated BMI does not adversely affect infant growth or body composition through the first postnatal year, suggesting safety of modest maternal weight loss in late pregnancy.